Mayur Narkhede, MD
Hematology & Oncology · Birmingham, ALNPI 1730529777
Payments from drug & device makers
Across 716 payments — averaging $6886.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genmab A/s$3M
- Genentech, Inc.$866K
- TG Therapeutics, Inc.$315K
- Beone Medicines USA, Inc.$276K
- Gilead$104K
- Beigene USA, Inc.$91K
- plus $278K from 18 others
Across 13 payments — averaging $6865.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Recordati_rare_diseases_inc.$88K
- Genmab A/s$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genmab A/s | 292 | $3,000,837 |
| Genentech, Inc. | 105 | $865,918 |
| TG Therapeutics, Inc. | 63 | $315,194 |
| Beone Medicines USA, Inc. | 32 | $275,972 |
| Gilead(2 entities) | 20 | $104,236 |
| Beigene USA, Inc. | 24 | $90,838 |
| Beigene, Ltd. | 25 | $76,619 |
| ADC Therapeutics America, Inc. | 29 | $63,980 |
| Genentech USA, Inc. | 33 | $37,539 |
| Lilly USA, LLC | 13 | $25,694 |
| Incyte Corporation | 14 | $25,498 |
| AbbVie | 29 | $21,106 |
| AstraZeneca | 6 | $6,842 |
| Seagen Inc. | 4 | $5,881 |
| Recordati_rare_diseases_inc. | 5 | $5,145 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $4,725 |
| Ipsen Biopharmaceuticals, Inc | 3 | $2,727 |
| Janssen Scientific Affairs, LLC | 1 | $1,363 |
| Secura Bio, Inc. | 3 | $257 |
| EUSA Pharma (US) LLC | 1 | $119 |
| Morphosys, US Inc. | 7 | $98 |
| Johnson & Johnson | 1 | $97 |
| Genmab U.S., Inc. | 1 | $58 |
| Epizyme, Inc. | 1 | $30 |
How this compares
$4,930,770 in reported general payments places this provider in the 95th percentile of 177 hematology & oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Birmingham
- Luciano CostaBirmingham$32.8M
- Amitkumar MehtaBirmingham$18.6M
- Erica Stringer-ReasorBirmingham$18.1M
- Susan BalBirmingham$11.3M
- Pankit VachhaniBirmingham$7.9M
- Mehmet AkceBirmingham$5.4M
- Christos VaklavasBirmingham$4.9M
- Lisle NabellBirmingham$3.3M
- Omer JamyBirmingham$2.7M
- Francisco VizcarrondoBirmingham$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.